Daiichi Sankyo Company, Limited
4568.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.77T
Close$
$2346.84
10.5% downside
Current Fair Value
10.5% downsideOvervalued by 10.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.77 Trillion |
|---|---|
| Enterprise Value | $4.71 Trillion |
| Dividend Yield | $78.00 (3.39%) |
| Earnings per Share | $140.44 |
| Beta | 0.8 |
| Outstanding Shares | 1,819,826,000 |
Return
| Return on Equity | 14.61% |
|---|---|
| Return on Assets | 6.04% |
| Return on Invested Capital | 7.02% |
Valuation & Multiples
| P/E Ratio | 19.86 |
|---|---|
| PEG | -106.38 |
| Price to Sales | 2.11 |
| Price to Book Ratio | 2.82 |
| Enterprise Value to Revenue | 2.08 |
| Enterprise Value to EBIT | 20.19 |
| Enterprise Value to Net Income | 19 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 0.34 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 31, 2026
EPS Estimate
$40.70
Average shareholder expectationRevenue Estimate
$533.71 B
Average shareholder expectationNext Earnings Call
Expected Date
October 30, 2026
EPS Estimate
$39.84
Average shareholder expectationRevenue Estimate
$568.88 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Daiichi Sankyo Company, Limited
20,171 employees
CEO: Hiroyuki Okuzawa Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively involved in the research, development, manufacturing, importation, marketing, and distribution of a diverse array of medicinal products worldwide. Its extensi...